Roche Holding and the Innovative Medicines Initiative are establishing StemBANCC, a new academic-industry collaboration that aims to use human induced pluripotent stem cells as tools for drug discovery and research. The project will include 10 drugmakers and 23 academic institutions studying the use of human iPS cells for the identification of drug targets and biomarkers and the screening of drug benefits and toxicology. "The aim of StemBANCC is to generate and characterize 1,500 high-quality human induced pluripotent stem cell lines derived from 500 patients that can be used by researchers to study a range of diseases including diabetes and dementia," project coordinator Martin Graf said.
Roche launches academic-industry stem cell initiative
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||